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Aims We examined the prognostic importance of N-terminal pro B-type natriuretic peptide (NT-proBNP) and troponin
T (TnT) in heart failure patients with and without diabetes.
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Methods
and results
We measured NT-proBNP and TnT in the biomarker substudy of the Prospective Comparison of ARNI With ACEI
to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF). Of 1907 patients, 759
(40%) had diabetes. Median TnT in patients with diabetes was 18 (interquartile range 11–27) ng/L and 13 (9–21)
ng/L in those without (P< 0.001). The TnT frequency-distribution curve was shifted to the right in patients with
diabetes, compared to those without diabetes. By contrast, NT-proBNP did not differ between patients with and
without diabetes. Diabetes and each biomarker were predictive of worse outcomes. Thus, patients with diabetes, an
elevated TnT and a NT-proBNP level in the highest tertile (9% of all patients) had an absolute risk of cardiovascular
death or heart failure hospitalization of 265 per 1000 person-years, compared to a rate of 42 per 1000 person-years
in those without diabetes, a TnT < 18 ng/L and a NT-proBNP in the lowest tertile (16% of all patients). TnT remained
an independent predictor of adverse outcomes in multivariable analyses including NT-proBNP.
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Conclusion TnT is elevated to a greater extent in heart failure patients with diabetes compared to those without (whereas
NT-proBNP is not). TnT and NT-proBNP are additive in predicting risk and when combined help identify diabetes
patients at extremely high absolute risk.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Troponin • NT-proBNP • Diabetes • Heart failure with reduced ejection fraction
Introduction
Circulating B-type natriuretic peptides are now measured routinely
in patients with heart failure (HF) and it is well established that
their levels are predictive of adverse clinical outcomes in these
patients.1–4 More recently, it has been demonstrated that B-type
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.. natriuretic peptides are also predictive of cardiovascular outcomes
and mortality in patients with type 2 diabetes mellitus.5–7
Although initially introduced to diagnose myocardial infarction in
patients with suspected acute coronary syndromes, high-sensitivity
assays have demonstrated that elevated circulating troponin can
be measured in most patients with HF and reduced ejection
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fraction (HFrEF). There is now a strong evidence base that troponin
concentration is also predictive of outcomes in these patients.4,8,9
Latterly this has also been shown to be true in individuals with
diabetes.10–12
However, troponin is not routinely measured in ambulatory
patients with HF (or diabetes). We do not know how concentra-
tions of these two peptides compare between HF patients with and
without diabetes, with the potential confounding influences of renal
impairment (which elevates both peptides), myocardial ischaemia
(with coronary macro- and microvascular disease more common
in individuals with diabetes) and obesity (which is associated with
lower levels of natriuretic peptides and more common in individ-
uals with diabetes).13 Likewise, we do not know their individual
and combined predictive value in HF patients with and without
diabetes. Specifically, does troponin add meaningful additional prog-
nostic information to measurement of a B-type natriuretic peptide
(BNP) in HFrEF patients with and without diabetes, irrespective of
HF aetiology (ischaemic or non-ischaemic)?
We examined these questions in the Prospective Comparison
of ARNI With ACEI to Determine Impact on Global Mortality and
Morbidity in Heart Failure (PARADIGM-HF), a large multicentre
randomized controlled trial with long-term follow-up for fatal and
non-fatal outcomes in patients with HFrEF.
Methods
Study design and patients
The background, design and primary results of the PARADIGM-HF
trial are published.14–16 In brief, 8399 patients in New York Heart
Association (NYHA) functional class II–IV with a left ventricular ejec-
tion fraction (LVEF) ≤ 40% receiving recommended treatment for
HFrEF including an angiotensin-converting enzyme (ACE) inhibitor or
angiotensin receptor blocker (ARB) and a beta-blocker (unless con-
traindicated) and a mineralocorticoid receptor antagonist (MRA) (if
indicated) were enrolled. Patients were required to have a plasma BNP
≥ 150 pg/mL [or N-terminal pro-BNP (NT-proBNP) ≥ 600 pg/mL], or
a BNP ≥ 100 pg/mL (or NT-proBNP ≥ 400 pg/mL) and a HF hospital-
ization within the past 12months. The key exclusion criteria included
intolerance of ACE inhibitors or ARBs, a history of angioedema, symp-
tomatic hypotension, a systolic blood pressure (SBP) < 100mmHg at
screening (< 95mmHg at randomization), an estimated glomerular fil-
tration rate (eGFR) < 30mL/min/1.73m2, and a serum potassium level
> 5.2mmol/L at screening (> 5.4mmol/L at randomization). Patients
were randomized to sacubitril/valsartan (formerly known as LCZ696)
or enalapril. Sacubitril/valsartan was superior to enalapril in reduc-
ing the risks of the primary composite endpoint of cardiovascular
death or HF hospitalization, its components and all-cause mortality.
Of all patients randomized, 1907 (23%) were enrolled in a prospec-
tive biomarker substudy and had a measurement of high-sensitivity
troponin T (TnT) in addition to NT-proBNP.
Definitions of diabetes mellitus
and ischaemic aetiology
Diagnosis of diabetes at baseline and aetiology (ischaemic/non-
ischaemic) was based on investigator responses to the relevant
questions in the case report form. ..
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.. Outcomes
We investigated the association between TnT and NT-proBNP, alone
and in combination, and the primary composite outcome and all-cause
mortality.
Laboratory analyses
All samples were collected at the randomization visit. Sample handling
and biomarker measurement using the Roche Elecsys NT-proBNP
(Roche Diagnostics, Indianapolis, IN, USA) and the fifth generation
high-sensitivity TnT assay (Roche Diagnostics GmbH, Mannheim, Ger-
many) have been described previously.17,18
Statistical analyses
Baseline characteristics are described by use of proportions for cat-
egorical variables and means with standard deviations or medians
with quartiles for continuous variables. Differences in baseline charac-
teristics between patients with and without diabetes were tested using
a 𝜒2 test for categorical variables and ANOVA or Kruskal–Wallis’s
test for continuous variables. Kaplan–Meier curves for all-cause mor-
tality and cumulative incidence curves for the primary endpoint were
estimated and differences between groups were compared by use of
log-rank and Gray’s test, respectively. Cox proportional hazard mod-
els were used to compare the risk of patients according to diabetes
status and levels of TnT and NT-proBNP for the primary endpoint
and all-cause mortality. The Cox regression models were adjusted
for age, sex, randomized treatment, ejection fraction, NYHA class,
body mass index, loge(NT-proBNP), heart rate, systolic blood pres-
sure, creatinine, low-density lipoprotein (LDL), prior angina pectoris,
atrial fibrillation, and pacemaker implantation. The assumption of lin-
earity was tested for TnT, age, ejection fraction, and NT-proBNP.
Log [–log(survival)] curves were used to evaluate the proportional
hazard assumption. Tests for interactions of diabetes status, age and
sex with TnT and NT-proBNP in relation to all outcomes were per-
formed. Model discrimination was tested by use of Harrell’s c-statistic,
the integrated discrimination improvement and the continuous net
reclassification index adapted for survival models.19,20 The associations
between TnT and NT-proBNP and outcomes were examined using the
biomarkers in a categorical way and as continuous variables, accord-
ing to history of diabetes and aetiology. TnT was dichotomized at or
above/below the recently recommended threshold for prognostication
in HF (18 ng/L) and NT-proBNP divided by tertiles.21 The biomark-
ers were examined as continuous variables in an adjusted model using
restricted cubic splines. P-values of < 0.05 were considered significant.
Analyses were performed using Stata version 15 and R version 3.3.2
(Stata Corp., College Station, TX, USA).
Results
Baseline characteristics
Among the patients (n=1907) in the biomarker substudy, 759
(40%) had diabetes. Patients with diabetes had a higher body mass
index, systolic blood pressure, and a lower LDL, high-density
lipoprotein and eGFR, compared to those without diabetes
(Table 1). A larger proportion of patients with diabetes had
a history of hypertension, myocardial infarction and coronary
revascularization than those without diabetes. Diuretic use and
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics according to diabetes status
No diabetes Diabetes P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patients, n (%) 1148 (60) 759 (40)
Female sex, n (%) 223 (19) 136 (18) 0.41
Age, years, mean± SD 66±10 67± 9 0.12
Ischaemic aetiology, n (%) 700 (61) 533 (70) <0.001
White, n (%) 1094 (95) 717 (95) 0.42
Randomized to sacubitril/valsartan, n (%) 573 (50) 378 (50) 0.96
HbA1c, %, median [Q1–Q3] 6.0 [5.7–6.3] 7.0 [6.3–7.9] <0.001
Ejection fraction, %, mean± SD 30± 6 30± 6 0.94
NYHA class, n (%) 0.52
I 29 (3) 16 (2)
II 845 (74) 541 (71)
III 265 (23) 197 (26)
IV 7 (0.6) 5 (0.7)
Body mass index, kg/m2, median [Q1–Q3] 28 [25–31] 30 [27–34] <0.001
Heart rate, b.p.m., median [IQR] 70 [62–79] 70 [64–80] 0.04
SBP, mmHg, median [IQR] 120 [110–131] 124 [113–135] <0.001
eGFR, mL/min/ 1.73m2, median [IQR] 65 [52–77] 61 [48–73] <0.001
Creatinine, 𝜇mol/L, median [IQR] 97 [83–116] 102 [87–123] <0.001
Cholesterol, mmol/L, median [IQR]
Total 4.6 [3.9–5.4] 4.3 [3.6–5.0] <0.001
Low-density lipoprotein 2.5 [2.0–3.2] 2.2 [1.7–2.8] <0.001
High-density lipoprotein 1.3 [1.1–1.5] 1.1 [1.0–1.4] <0.001
Current smoker, n (%) 156 (14) 94 (12) 0.45
Oedema, n (%) 251 (21) 175 (23) 0.54
Rales, n (%) 100 (9) 66 (9) 0.99
Third heart sound, n (%) 71 (6) 57 (8) 0.26
Jugular vein distention, n (%) 113 (10) 60 (8) 0.15
Orthopnoea, n (%) 68 (6) 55 (7) 0.25
Dyspnoea on effort, n (%) 1024 (89) 694 (91) 0.13
Dyspnoea at rest, n (%) 52 (5) 33 (4) 0.84
Medical history, n (%)
Angina 338 (29) 244 (32) 0.21
CABG or PCI 448 (39) 413 (54) <0.001
Pacemaker 221 (19) 176 (23) 0.04
ICD 291 (25) 247 (33) <0.001
Atrial fibrillation 551 (48) 377 (50) 0.47
Hypertension 837 (73) 650 (86) <0.001
Myocardial infarction 525 (47) 411 (54) <0.001
Intermittent claudication 54 (5) 70 (9) <0.001
Stroke 114 (10) 79 (10) 0.74
Current medication, n (%)
Diuretics 920 (80) 648 (85) 0.003
ACEI or ARB 1148 (100) 759 (100) –
Beta-blockers 1092 (95) 723 (95) 0.89
MRA 510 (44) 349 (46) 0.50
Digoxin 239 (21) 184 (24) 0.08
Antiplatelets 643 (56) 450 (59) 0.16
Anticoagulants 498 (43) 331 (44) 0.92
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; HbA1c,
glycated haemoglobin; ICD, implantable cardioverter defibrillator; IQR, interquartile range; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association;
PCI, percutaneous coronary intervention; Q, quartile; SBP, systolic blood pressure; SD, standard deviation.
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Table 2 Baseline characteristics of patients with and without a troponin T measurement
Measurement of TnT No measurement of TnT P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patients, n (%) 1907 (23) 6492 (77)
Female sex, n (%) 359 (19) 1473 (23) <0.001
Age, years, mean± SD 67±10 62±11 <0.001
Ischaemic aetiology, n (%) 1233 (65) 3803 (59) <0.001
White, n (%) 1811 (95) 3733 (58) <0.001
Randomized to sacubitril/valsartan, n (%) 951 (50) 3236 (50) 0.99
NT-proBNP, pg/mL, median [Q1–Q3] 1481 [855–2812] 1671 [903–3400] <0.001
Ejection fraction, %, mean± SD 30± 6 29± 6 <0.001
NYHA class, n (%) <0.001
I 45 (2) 344 (5)
II 1386 (73) 4533 (70)
III 462 (24) 1556 (24)
IV 12 (0.6) 48 (0.7)
Body mass index, kg/m2, median [Q1–Q3] 29 [26–32] 27 [24–31] <0.001
Heart rate, b.p.m., median [IQR] 70 [63–79] 72 [64–80] <0.001
SBP, mmHg, median [IQR] 121 [110–132] 120 [110–130] <0.001
eGFR, mL/min/ 1.73m2, median [IQR] 63 [51–75] 67 [55–81] <0.001
Creatinine, 𝜇mol/L, median [IQR] 99 [85–119] 94 [80–112] <0.001
Cholesterol, mmol/L, median [IQR]
Total 4.4 [3.8–5.3] 4.4 [3.8–5.3] 0.8358
Low-density lipoprotein 2.4 [1.8–3.1] 2.4 [1.9–3.1] 0.1377
High-density lipoprotein 1.2 [1.0–1.5] 1.2 [1.0–1.4] <0.001
Current smoker, n (%) 250 (13) 958 (15) 0.0715
Medical history, n (%)
Diabetes 759 (40) 2148 (33) <0.001
Angina 582 (31) 1722 (27) <0.001
CABG or PCI 861 (45) 1779 (27) <0.001
Pacemaker 538 (28) 705 (11) <0.001
ICD 397 (21) 691 (11) <0.001
Atrial fibrillation 928 (49) 2163 (33) <0.001
Hypertension 1487 (78) 4453 (69) <0.001
Myocardial infarction 936 (49) 2698 (42) <0.001
Intermittent claudication 124 (7) 268 (4) <0.001
Stroke 193 (10) 532 (8) 0.009
Current medication, n (%)
Diuretics 1568 (82) 5170 (80) 0.01
ACEI or ARB 1907 (100) 6472 (100) 0.02
Beta-blockers 1815 (95) 5996 (92) <0.001
MRA 859 (45) 3812 (59) <0.001
Digoxin 423 (22) 2116 (33) <0.001
Antiplatelets 1093 (57) 3643 (56) 0.35
Anticoagulants 829 (44) 1856 (29) <0.001
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease;
eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter defibrillator; IQR, interquartile range; MRA, mineralocorticoid receptor antagonist; NT-proBNP,
N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; Q, quartile; SBP, systolic blood pressure; SD,
standard deviation; TnT, troponin T.
prior implantable cardioverter defibrillator implantation were also
more common in individuals with diabetes. Most patients were
in NYHA functional class II and the distribution of NYHA class
did not differ significantly between patients with and without
diabetes.
Patients with HF of ischaemic origin (65%) were older, had a
lower eGFR and less use of diuretics and digoxin than patients
with non-ischaemic aetiology. Fewer ischaemic patients had atrial ..
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. fibrillation compared to those with non-ischaemic HF, irrespective
of diabetes status (online supplementary Table S1). Patients in
the biomarker substudy differed from those not included in a
number of ways. They were older, more were men and they had a
different racial composition, compared with patients not included
in the biomarker substudy. A higher proportion had an ischaemic
aetiology and they had a greater burden of co-morbidities, including
more obesity and renal impairment (Table 2).
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Table 3 Troponin T and N-terminal pro B-type natriuretic peptide levels according to diabetes status
No diabetes Diabetes P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Troponin T, ng/L, median [IQR]
Overall 13 [9–21] 18 [11–27] <0.001
Ischaemic 13 [8–20] 18 [12–27]
Non-ischaemic 13 [9–20] 16 [11–24]
Troponin T≥18 ng/L, n (%)
Overall 394 (34) 382 (50) <0.001
Ischaemic 241 (34) 279 (52)
Non-ischaemic 153 (34) 103 (46)
NT-proBNP, pg/mL, median [IQR]
Overall 906 [516–1725] 890 [538–1585] 0.51
Ischaemic 988 [538–1782] 883 [538–1654]
Non-ischaemic 830 [455–1591] 916 [542–1465]
NT-proBNP - tertile 3, n (%)
Overall 395 (34) 240 (32) 0.38
Ischaemic 253 (36) 173 (32)
Non-ischaemic 142 (32) 67 (30)
IQR, interquartile range; NT-proBNP, N-terminal pro B-type natriuretic peptide.
Concentrations of troponin T
The median concentration of TnT at baseline was significantly
higher in patients with diabetes [18 ng/L, interquartile range (IQR)
11–27 ng/L] compared to patients without diabetes (13 ng/L, IQR
9–21 ng/L) (P< 0.001). Half of patients with diabetes had a TnT
value ≥18 ng/L compared to a third of those without diabetes
(Table 3). These findings were consistent when patients were com-
pared according to aetiology of HF (ischaemic or non-ischaemic)
(Table 3).
The distribution of plasma TnT concentrations in
patients with and without diabetes, stratified by aetiology
(ischaemic/non-ischaemic) is shown in Figure 1. The frequency
distribution curve was shifted to the right in patients with dia-
betes, compared to those without diabetes, in both ischaemic and
non-ischaemic HFrEF patients; this pattern was quite distinct from
that seen for NT-proBNP (see below).
Concentrations of NT-proBNP
In contrast to TnT, patients with diabetes and without diabetes had
similar median levels of NT-proBNP at baseline (890 pg/mL, IQR
538–1585 pg/mL vs. 906 pg/mL, IQR 516–1725 pg/mL; P= 0.51).
Around a third of patients with and without diabetes had a
NT-proBNP value in the top tertile (i.e. >1342 pg/mL; P= 0.38)
(Table 3). Median NT-proBNP levels were also similar in patients
with and without diabetes, irrespective of aetiology (ischaemic
or non-ischaemic). In contrast to TnT, the frequency distribution
curves for concentration of NT-proBNP were similar in patients
with and without diabetes, in both ischaemic and non-ischaemic
HFrEF patients (Figure 1).
Baseline troponin T and clinical
outcomes
During follow-up, patients with TnT ≥ 18 ng/L had a significantly
higher risk of the composite outcome of cardiovascular death or ..
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. HF hospitalization, irrespective of diabetes status and ischaemic
or non-ischaemic aetiology (Figure 2). Patients with diabetes were
at higher risk than those without and patients with an ischaemic
aetiology were at a higher risk than those with a non-ischaemic
aetiology. Consequently, patients with diabetes and ischaemic HF
and an elevated TnT were at a very high absolute risk (203
per 1000 person-years) compared to those without diabetes,
a non-ischaemic aetiology who had a TnT < 18 ng/L (46 per
1000 person-years).
The elevated risk related to TnT persisted in adjusted Cox
regression models incorporating TnT in a categorical way (≥18
vs. < 18 ng/L) or as a continuous variable (per loge increase in
TnT) (Table 4). The relationship between TnT and the composite
outcome of cardiovascular death or HF hospitalization was similar
in patients with and without diabetes, across the spectrum of TnT
concentrations, with a linear increase in risk of 91% and 73%
in patients with and without diabetes, respectively, per log unit
increase in TnT (Table 4 and online supplementary Figure S1).
Baseline NT-proBNP and clinical
outcomes
Patients with NT-proBNP in the highest tertile had a significantly
higher risk of the composite outcome of cardiovascular death or
HF hospitalization, irrespective of diabetes status and ischaemic or
non-ischaemic aetiology. Patients with diabetes and an ischaemic
aetiology were at the highest risk of all outcomes. Thus, patients
with diabetes and ischaemic HF and NT-proBNP in the high-
est tertile were at a very high absolute risk of the compos-
ite outcome of cardiovascular death or HF hospitalization (267
per 1000 person-years) compared to those without diabetes, a
non-ischaemic aetiology and NT-proBNP in the lowest tertile (53
per 100 person-years).
In adjusted Cox regression models incorporating NT-proBNP
as tertiles or as a continuous variable (per loge increase in
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Distribution of troponin T and N-terminal pro B-type natriuretic peptide (NT-proBNP) according to diabetes status and heart
failure aetiology in PARADIGM-HF. (A) Troponin T in patients with ischaemic heart failure. (B) Troponin T in patients with non-ischaemic heart
failure. (C) NT-proBNP in patients with ischaemic heart failure. (D) NT-proBNP in patients with non-ischaemic heart failure.
NT-proBNP), the elevated risk associated with increased lev-
els of NT-proBNP persisted (Table 4). The relationship between
NT-proBNP and the composite outcome of cardiovascular death
or HF hospitalization was similar in patients with and without dia-
betes, across the spectrum of NT-proBNP concentrations (online
supplementary Figure S2).
Combination of troponin T
and NT-proBNP in predicting clinical
outcomes
The risks associated with TnT and NT-proBNP were additive
in predicting outcomes, both in patients with and without diabetes.
Thus, patients with diabetes, an elevated TnT and a NT-proBNP
level in the highest tertile (n= 178, 9% of all patients) had
an absolute risk of the primary composite outcome of
265 per 1000 person-years, compared to a rate of 42 per
1000 person-years in those without diabetes, a TnT < 18 ng/L and
a NT-proBNP in the lowest tertile (n= 305, 16% of all patients).
This contrast in absolute rates was even more striking when ..
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. ischaemic aetiology was also considered. Patients with an ischaemic
aetiology, diabetes, an elevated TnT and a NT-proBNP level in the
highest tertile (n= 130, 7% of all patients) had an absolute risk of
the primary composite outcome of 295 per 1000 person-years,
compared to a rate of 40 per 1000 person-years in those with
non-ischaemic HF, without diabetes, a TnT < 18 ng/L and a
NT-proBNP in the lowest tertile (n=133, 7% of all patients).
In multivariable predictive models, among patients with diabetes,
those having a TnT level ≥18 ng/L and a NT-proBNP in the high-
est tertile had a 4.5-fold higher risk (4.1 for ischaemic and 15.6
for non-ischaemic patients) of the primary outcome, compared to
those with a TnT < 18 ng/L and a NT-proBNP in the lowest ter-
tile. The risk was 4.2-fold higher (3.6 for ischaemic and 5.0 for
non-ischaemic patients) in individuals without diabetes (Figure 3).
Among patients with diabetes, TnT and NT-proBNP were associ-
ated with increased risk of cardiovascular death or HF hospitaliza-
tion, irrespective of glycated haemoglobin levels (data not shown).
Troponin T added significant discriminatory power to the mod-
els predicting cardiovascular death or HF hospitalization, although
the effect sizes were modest (online supplementary Table S2). In
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Figure 2 Cumulative incidence of heart failure hospitalization or cardiovascular death with death as competing risk according to troponin T
(TnT) ≥18 or <18 ng/L among patients with and without heart failure of ischaemic origin and diabetes in PARADIGM-HF. (A) Patients with
no diabetes and heart failure of ischaemic origin. (B) Patients with diabetes and heart failure of ischaemic origin. (C) Patients with no diabetes
and heart failure of non-ischaemic origin. (D) Patients with diabetes and heart failure of non-ischaemic origin.
models with all-cause mortality as outcome, only the integrated
discrimination improvement was improved when TnT was added
to the models.
Discussion
This study has three key findings. First, HFrEF patients with dia-
betes had higher concentrations of TnT, compared to HFrEF
patients without diabetes, and this was true for patients with non-
ischaemic HF, as well as those with an ischaemic aetiology. This ..
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.. contrasted to the lack of difference in NT-proBNP between
patients with and without diabetes. Second, higher levels of TnT
and NT-proBNP were each associated with worse outcomes, irre-
spective of diabetes status and HF aetiology, i.e. diabetes did not
alter the prognostic performance of either biomarker. TnT was an
independent predictor of outcomes when added to a multivariable
model including NT-proBNP. The risks associated with increas-
ing levels of the two biomarkers were additive, and this additiv-
ity was similar in individuals with and without diabetes. Thirdly,
as a result of the foregoing, and perhaps most importantly clini-
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Table 4 Adjusted hazard ratios for cardiovascular death/heart failure hospitalization and all-cause mortality
according to troponin T and N-terminal pro B-type natriuretic peptide levels
HR (95% CI)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
No diabetes Diabetes
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CV death/HF hospitalization
Troponin T
<18 ng/L 1.00 (ref) 1.00 (ref)
≥18 ng/L 1.65 (1.20–2.28) 1.49 (1.05–2.12)
Per loge increase 1.73 (1.34–2.23) 1.91 (1.45–2.51)
NT-proBNP
T1 1.00 (ref) 1.00 (ref)
T2 1.33 (0.88–2.01) 1.75 (1.15–2.67)
T3 2.77 (1.88–4.07) 3.35 (2.19–5.11)
Per loge increase 1.64 (1.40–1.93) 1.85 (1.54–2.23)
All-cause mortality
Troponin T
<18 ng/L 1.00 (ref) 1.00 (ref)
≥18 ng/L 1.51 (1.05–2.17) 1.49 (1.01–2.26)
Per loge increase 1.66 (1.24–2.22) 1.71 (1.23–2.37)
NT-proBNP
T1 1.00 (ref) 1.00 (ref)
T2 1.41 (0.87–2.27) 2.00 (1.19–3.37)
T3 2.45 (1.55–3.86) 3.34 (1.98–5.65)
Per loge increase 1.51 (1.26–1.82) 1.60 (1.30–1.97)
CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; NT-proBNP, N-terminal pro B-type natriuretic peptide.
All models were adjusted for age, sex, treatment effect, ejection fraction, New York Heart Association class, body mass index, heart rate, systolic blood pressure, creatinine,
low-density lipoprotein, prior angina pectoris, atrial fibrillation and pacemaker implantation. Models with troponin T levels as exposure were also adjusted for loge(NT-proBNP).
cally, these biomarkers used in combination with patient pheno-
type identified individuals at remarkably high absolute risk. For
example, those with the triad of diabetes, an ischaemic aetiol-
ogy and an elevated TnT had a primary endpoint rate of 203
per 1000 person-years (compared with 46 per 1000 person-years
in those with non-ischaemic HF, no diabetes and a TnT < 18 ng/L).
A few prior studies have reported that patients with diabetes
have elevated levels of TnT and, in HF patients, diabetes seems to
be more prevalent among those with high levels of TnT.8,10,11,22
In accordance with this, we found higher average levels of TnT
in HFrEF patients with diabetes compared to those without
diabetes. Using the newly recommended TnT prognostication
threshold for HF of ≥ 18 ng/L, we found that the proportion of
diabetes patients with an elevated TnT was 50% compared to
34% of patients without diabetes. The most obvious explanation
for more frequent elevation of TnT in patients with diabetes is
the higher prevalence of coronary artery disease in those indi-
viduals. However, we found TnT was similarly elevated in patients
with non-ischaemic and ischaemic HFrEF. Diabetes also causes
microvascular disease and this may lead to myocardial ischaemia
and cardiomyocyte injury in the absence of or in addition to
macrovascular coronary disease.23 Unfortunately, information on
microvascular complications was not collected in PARADIGM-HF.
An alternative explanation might be the greater likelihood of renal
dysfunction in patients with diabetes, as renal dysfunction is also
associated with raised troponin concentrations.24–26 However, ..
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.. there was only a small difference in eGFR and creatinine between
those with and without diabetes, and NT-proBNP, levels of which
are also influenced by renal function, did not differ between those
with and without diabetes. Additional pathophysiologic processes
operating in patients with diabetes might cause cardiomyocyte
injury. For example, inflammation appears to be more common in
individuals with diabetes compared to those without.27
Elevation of TnT has previously been associated with worse
prognosis in each of HFrEF and diabetes.8,12 Our study adds to
these prior findings by showing that TnT is an independent pre-
dictor of adverse outcomes in patients with these two conditions
combined, even when added to a multivariable model contain-
ing NT-proBNP, which is in itself the single most powerful pre-
dictor of prognosis in HFrEF.28–30 That the prognostic value of
TnT is similar in HFrEF patients with and without diabetes is
important, given the greater prevalence of elevated concentrations
of TnT in individuals with diabetes. This highlights the consider-
able contribution of TnT to population-attributable risk in HFrEF
patients with diabetes. Moreover, this could be important and rel-
evant for clinical practice as by use of both routinely-available
and relatively inexpensive biomarkers combined with a diabetic
phenotype (and especially a diabetic, ischaemic phenotype) we
were able to identify an extremely high-risk subset of patients
in PARADIGM-HF. Such patients may merit close surveillance,
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Figure 3 Risk of cardiovascular death or heart failure hos-
pitalization according to troponin T (TnT) ≥18 or <18 ng/L
and tertiles of N-terminal pro B-type natriuretic peptide
(NT-proBNP) levels among patients with and without diabetes
in PARADIGM-HF (A: no diabetes; B: diabetes). Adjusted for age,
sex, treatment effect, ejection fraction, New York Heart Associ-
ation class, body mass index, heart rate, systolic blood pressure,
creatinine, low-density lipoprotein, prior angina pectoris, atrial
fibrillation, and pacemaker implantation.
appropriate counselling, intensive efforts to optimize pharmacolog-
ical, device and surgical therapies (including coronary revasculariza-
tion). This sizeable minority of patients might also be the target for
new strategies to lower risk.
Limitations
Both biomarkers were only available in the pre-specified biomarker
substudy of approximately 2000 patients, and the characteristics
of these patients were significantly different from the patients not
included in the biomarker substudy. Diabetes status and ischaemic
aetiology were investigator reported and a degree of misclas-
sification will have occurred as, for example, it is known that
some HFrEF patients have undiagnosed diabetes and some patients
with a presumed non-ischaemic HFrEF aetiology are found to have
coronary artery disease on angiography or at autopsy. However,
the clinical characteristics and difference in event rates between
patients with the different phenotypes of interest suggest at least
reasonably accurate categorization. ..
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.. Conclusions
In HFrEF, patients with diabetes had higher levels of TnT than
patients without diabetes, contrasting with NT-proBNP, which did
not differ between patients with and without diabetes. TnT was
similarly elevated in ischaemic and non-ischaemic patients. TnT was
independently predictive of outcomes, when added to a multivari-
able model including NT-proBNP, irrespective of diabetes status.
TnT and NT-proBNP are therefore additive in predicting risk and,
when combined with clinical phenotype (diabetes, ischaemic aeti-
ology), help identify patients at extremely high absolute risk.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Figure S1. Risk of cardiovascular death or heart failure hospi-
talization according to troponin T levels among patients with and
without diabetes in PARADIGM-HF (A: no diabetes; B: diabetes).
Adjusted for loge(NT-proBNP), age, sex, treatment effect, ejection
fraction, New York Heart Association class, body mass index, heart
rate, systolic blood pressure, creatinine, low-density lipoprotein,
prior angina pectoris, atrial fibrillation and pacemaker implantation.
Figure S2. Risk of cardiovascular death or heart failure hospi-
talization according to N-terminal pro B-type natriuretic peptide
(NT-proBNP) levels among patients with and without diabetes in
PARADIGM-HF (A: no diabetes; B: diabetes). Adjusted for age,
sex, treatment effect, ejection fraction, New York Heart Associ-
ation class, body mass index, heart rate, systolic blood pressure,
creatinine, low-density lipoprotein, prior angina pectoris, atrial fib-
rillation and pacemaker implantation.
Table S1. Baseline characteristics according to diabetes status and
heart failure aetiology.
Table S2. C-index, net reclassification index and integrated dis-
crimination improvement for the added effect of troponin T to the
baseline model.
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